胶质母细胞瘤患者凝血谱的意义与预后价值:对个体化治疗的启示
研究采集58例胶质母细胞瘤(GBM)和22例脑膜瘤(MNG)患者治疗前血样,检测凝血与纤溶指标。GBM组凝血酶原时间(PT)和活化部分凝血活酶时间(aPTT)显著低于MNG组,D二聚体(DD)、血管性血友病因子抗原(VWF:Ag)和白细胞计数显著高于MNG组。GBM中高凝状态患者总生存期较非高凝患者缩短。
要点
- GBM患者治疗前呈现高凝状态,PT和aPTT降低,DD和VWF:Ag升高。
- GBM中高凝状态患者总生存期较非高凝患者缩短(P<0.05)。
- 凝血谱可能作为GBM预后因素并影响抗血栓预防决策。
核心结论
- GBM患者呈现血浆高凝状态,且凝血谱与不良预后相关;若被证实,高凝状态可能作为疾病预后因素并在抗血栓预防决策中起重要作用。
研究设计与样本
- 研究纳入58例胶质母细胞瘤(GBM)患者和22例脑膜瘤(MNG)患者,于任何治疗前采集血样,分析凝血与纤溶相关指标。
主要发现
- GBM组血浆PT和aPTT水平显著低于MNG组(P<0.05)。
- GBM组DD、VWF:Ag水平和白细胞计数显著高于MNG组(P<0.01)。
- GBM中PT和aPTT降低、DD和VWF升高的高凝状态患者,总生存期较非高凝患者缩短(P<0.05)。
临床怎么用
- 作者认为凝血谱可能作为GBM的预后因素,并可能影响抗血栓预防的决策。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Coagulation is an important aspect of the vascular microenvironment in which brain tumors evolve. Patients with tumor often show aberrant coagulation and fibrinolysis activation. In particular, glioblastoma (GBM), the most aggressive primary brain tumor, is associated with a state of hypercoagulability, and venous thromboembolism is a common complication of this cancer and its treatment. Our study aims to investigate the clinical and prognostic significance of routine laboratory tests to assess the coagulative state of patients with brain tumors, to identify potential new prognostic factors and targets for personalized therapy. METHODS: Blood samples were collected from patients with GBM (n = 58) and patients with meningioma (MNG, n = 22), before any treatment. The parameters analyzed were prothrombin time (PT), activated partial thromboplastin time (aPTT), D dimer (DD), fibrinogen, von Willebrand factor (VWF), leukocyte count, and hemoglobin levels. RESULTS: Plasma levels of PT and aPTT were significantly reduced in GBMs compared with MNGs (P < 0.05), whereas DD, VWF:Ag levels, and leukocyte count were significantly higher in GBMs than in MNGs (P < 0.01). Furthermore, we observed that patients with GBM with reduced PT and aPTT and high levels of DD and VWF, defined as hypercoagulable patients, showed reduced overall survival (P < 0.05) compared with nonhypercoagulable patients. CONCLUSIONS: Our data support the assumption that patients with GBM show a plasma hypercoagulable profile and that coagulation profile is related to adverse outcome in patients with GBM. If confirmed, hypercoagulability could play an important role as a prognostic factor of the disease and in the decision of an antithrombotic prophylaxis.
引用
- Navone SE, Guarnaccia L, Locatelli M, et al. Significance and Prognostic Value of The Coagulation Profile in Patients with Glioblastoma: Implications for Personalized Therapy. World Neurosurg. 2018. PMID: 30292037. doi:10.1016/j.wneu.2018.09.177
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。